GREAT-WALL-MOTOR
5.6.2019 11:19:08 CEST | Business Wire | Press release
At 12:06 on June 5, 2019, CZ-11 Solid-fuel Space Launch Vehicle (CZ-11 WEY) sees its first sea launch on the Yellow Sea, successfully sending seven satellites into the preset orbit and ushering in a new era of CASC development. The leading Chinese luxury SUV brand WEY is the first business partner of CASC. Both parties jointly call this launch vehicle as “CZ-11 WEY”, which marks a new breakthrough in business model of CASC. In addition, the Joint Technology Innovation Center co-initiated by CASC and WEY aims to put technologies into practice in the fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy through steady progress, so that the aero technology can be readily available.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005423/en/
CZ-11 Space Launch Vehicle is the first and only type of solid-fuel launch vehicles in the CZ Launch Vehicle Family. It is nearly 21 meters long and 58 tons weigh. Boasting a take-off thrust of 120 tons, it can carry up to 500 kg of payloads into the sun-synchronous orbit at a height of 500 km. This sea launch of CZ-11 WEY crystallizes the breakthroughs in a number of key technologies, such as wireless remote control at the front and rear terminals, independent intelligent security control on launcher, aiming of mobile base launching on the sea. CZ-11 Space Launch Vehicle has not only achieved China’s first-ever sea launch and low-inclination launch, but also created a new launch mode for Chinese launch vehicles into the space.
In conjunction with this sea launch, CASC and WEY steadily advance technical exchanges and cooperation in two fields. Both parties will promote integration in four fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy. They are committed to strongly empowering the independent R&D and manufacturing and creating greater market opportunities and economic value for CASC. Moreover, through technology application in the automotive industry, the aerospace technology can be readily available.
It is worth mentioning that Creative Experience Activity of “Dialogue with Parallel Universe” is jointly held by WEY and CASC. Through digital transmitter mounted on CZ-11 WEY Satellite, the voices of many consumers are transmitted to the outer space in the form of electric wave to “dialogue across the space” with another themselves in parallel universe. Compared with the international program of “Send Your Name to Mars with NASA’s next Mars Rover”, this sea launch is such a magnificent feat that retains the peoples’ voices and names in the space earlier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005423/en/
Contact:
Great Wall Motor Liu Jian +8618241766066 liujian@dsconsulting.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom